Cautious. GMAB's 38/100 Growth and Value scores reflect modest mid-single-digit revenue growth and ~15% ROIC—below compounder thresholds. Leadership alignment is middling (60/100): CEO compensation tied to revenue but no founder-CEO alignment or meaningful insider equity lock-in. The core vulnerability is thin financial resilience with cyclical biotech exposure, offering limited moat to absorb clinical or regulatory setbacks. At 19× forward P/E, valuation doesn't compensate for structural modest
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Genmab A/S:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 46/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Genmab A/S (GMAB) at 46/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. GMAB's 38/100 Growth and Value scores reflect modest mid-single-digit revenue growth and ~15% ROIC—below compounder thresholds. Leadership alignment is middling (60/100): CEO compensation tied to revenue but no founder-CEO ali
GMAB's current Stocky Verdict is 46/100, placing it in the "Cautious" band. This composite combines a 38/100 Compounder score, 60/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Genmab A/S yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Genmab A/S scores 60/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Genmab A/S's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Genmab A/S.
Sign up free and unlock the full analysis on GMAB — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for GMAB in the app.
